From its origins in ancient military time where the Romans and Greeks used logistics and distribution channels to supply their armies, to today's challenges with the supply chain for pharma ingredients, we enjoyed putting some questions to Univar...
Eli Lilly has invested in its manufacturing capacity once more and has announced plans to build a $2.5 billion high-tech manufacturing site in Germany.
Using a combination of pre-existing HIV drugs, a medicine for HIV-negative people taken before sex has reduced the chances of getting the virus by 86%.
A Life Sciences Advisory Board has been launched by Atropos Health, a company that translates data into personalized real-world insights across healthcare.
Volunteers with conditions including depression, alcohol use disorder, and anorexia are being sought by Clerkenwell Health, to join its seminal clinical trials.
The Janssen Pharmaceutical Companies of Johnson & Johnson announced last week (November 23) the submission of a type 2 extension of indication application to the European Medicines Agency (EMA).
An exciting new instrument that will help identify promising drug targets for academia and the pharma industry has been unveiled in Australia by The Monash Institute of Pharmaceutical Sciences (MIPS).
OSP had a discussion with Tracy Curley, CEO of iSpecimen, and Eric Langlois, chief revenue officer of iSpecimen and Michael Howell,founder of Mountaineer Biosciences, Inc. to discuss a number of issues those working in precision medicine still face.
OSP was delighted to talk to Vetter’s Carsten Press, a senior leader of the global sales organization, and business development among many operational functions.
Astellas Pharma Inc. and Pfizer Inc. today announced that the companies received approval from the US Food and Drug Administration (FDA) for a supplemental New Drug Application for small-molecule drug Xtandi (enzalutamide).
A partnership combining an integrated drug creation platform with a company specializing in dermatological expertise will deliver life-changing medicines to patients.
The first and only enzyme replacement therapy for the treatment of a very rare and complex blood disorder has been approved by the US Food and Drug Administration.
A partnership between clinical research technology company uMotif and cognitive science company, Cogstate Limited, will see the companies continue existing work that includes a major phase 2 clinical trial of a psychedelic therapeutic.
Vice president and global head of bioanalytical and central lab services, Lan Li has always found doctors fascinating. Their ability to save lives and give second chances set her on her career path, but it was recognizing there were still so many unmet...
The US Food and Drug Administration (FDA) has approved a potassium-competitive acid blocker (PCAB) as a new treatment for the healing of all grades of erosive esophagitis.
M&G Investments has made a $57 million investment with Swiss-based tech firm, SkyCell and says it is seeking to change the face of international pharma supply chains.
Integrated drug discovery contract research organization (CRO) Sygnature Discovery has invested £3.75 million in an Azenta compound management storage system that can also provide customer libraries.
Physics-powered GenAI Biotech, Gero, announced yesterday (October 18) that it had closed a $6 million series A extension round with funding from Melnicheck Investments and other investors.
AstraZeneca’s supplemental new drug application (sNDA) for lead lung cancer drug Tagrisso (Osimertinib) in combination with chemotherapy has been accepted and granted priority review in the US.
Calliditas Therapeutics says it is optimistic about getting full marketing authorization for a drug to treat primary IgA nephropathy (IgAN) after submitting a request to the European Medicines Agency (EMA).
Exscientia plc will receive an upfront cash payment of $20 million from Merck KGaA, Darmstadt, Germany, as the companies collaborate plus potential payments of up to $674 million in aggregate.
Insilico Medicine is due to receive $80 million upfront plus potential milestone payments as Exelixis gains global rights to develop and commercialize the Hong Kong firm’s small molecule cancer treatment.
Less than a month after the U.S. Food and Drug Administration (FDA) gave its antidepressant drug zuranolone (Zurzuvae) a mixed welcome, Sage Therapeutics has launched plans to reorganize its operations by refocusing its drug development efforts and laying...
The small molecule drug alectinib (Alecensa) developed by the big pharma company Roche has improved disease-free survival in patients with a specific form of non-small cell lung cancer (NSCLC) when delivered as an adjuvant therapy in a phase 3 trial.
QuantHealth announced it has raised a $15 million series A funding round today (August 22) for its clinical simulator that can predict how a patient will respond to treatment in a clinical trial.
A kidney disease drug with a ‘durable and clinically meaningful impact on kidney function’ has been granted priority review by the US Food and Drug Administration (FDA).
Patients suffering from catheter-related bloodstream infections could be treated with Citius Pharmaceuticals antibiotic lock solution after it achieved 92 milestone events in its phase 3 trial.
The National Health Service (NHS) research ethics committee has approved a non-cancer chronic pain clinical trial being rolled out by private health clinic LVL Health.
Drugs like Annovis Bio’s buntanetap and prasinezumab have the potential to “revolutionize the treatment of Parkinson’s Disease” says analytics company, GlobalData, an analytics company, but it is a complex road ahead.
Dr. Theresa Heah is the CEO of Intergalactic Therapeutics, bringing over two decades of global leadership experience in ophthalmology drug development along with commercialization in early-stage, private-staged companies. We spoke to her about her background,...
The world’s first anti-fibrotic small molecule inhibitor, discovered and designed by generative artificial intelligence (AI) has completed the first patient dose in a phase 2 clinical trial.
A small molecule drug candidate from Algiax Pharmaceuticals can reduce excitability of neurons in relation to chronic pain, dampening signal and reducing pain, a study shows.
Small molecule drug, Tagrisso (Osimertinib) taken alongside chemotherapy has showed a strong improvement in progression-free survival for patients with EGFR (epidermal growth factor receptor)-mutated advanced lung cancer, a phase 3 study has revealed.